一分钟看懂
这是一项关于白血病的I 期研究，登记的药物或干预包括Mosunetuzumab；Tocilizumab；Venetoclax；Rituximab，当前状态为招募中。登记地点显示中国北京、广州、南昌、天津有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Mosunetuzumab；Tocilizumab；Venetoclax；Rituximab · I 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Peking University People's Hospital · 北京
- Southern Medical University Nanfang Hospital · 广州
- The First Affiliated Hospital of Nanchang University · 南昌
- Tianjin Institute of Hematology & Blood Diseases Hospital · 天津
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Have a diagnosis of CLL requiring treatment according to the International Workshop on CLL (iwCLL) criteria (Hallek et al 2018)
- * Eastern Cooperative Oncology Group (ECOG) performance score (PS) of ≤ 2
- * Adequate bone marrow (BM) function independent of growth factor or transfusion support, within 2 weeks of screening, at screening as defined by the protocol unless cytopenia is clearly due to marrow involvement of CLL
- * Adequate liver function unless directly attributable to the participant's CLL
- * Life expectancy \> 6 months
- * For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year, and agreement to refrain from donating eggs during the treatment period and for at least 3 months after the last dose of mosunetuzumab and 3 months after the last dose of tocilizumab (if applicable)
- * For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm as defined by the protocol
- Inclusion Criteria Specific to Arm B:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05091424；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。